Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19583533 | 0.77 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29897771 | 0.77 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL27961755 | 0.74 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL9277382 | 0.72 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL19035841 | 0.70 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL4164273 | 0.70 | PNMT (0.88) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL7512740 | 0.70 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22271652 | 0.69 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1013537 | 0.69 | ALDH1A1 (0.52) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL7511868 | 0.69 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4558502-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034731-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDKN1A, CDK8 | PNMT 1213/4885ADRA2A 2431/4885ADRA2B 2001/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | PNMT 821/4885ADRA2A 628/4885ADRA2B 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.